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Abstract: 
Background: Ro- antigen is among many antigens that can be detected in SLE patients, with 
anti-Ro antibodies amounting to 90% in some patients. Although anti-Ro antibodies can be 
detected earlier than other antibodies, still their role is to be determined.                                                           
Aim: To estimate the occurrence of anti-Ro antibodies in patients with SLE, and its relation 
to classification criteria of the American College of Rheumatology (ACR) in Sudan.  
Materials and Methods: Eighty- six patients with SLE, recruited from two rheumatology 
clinics in Omdurman- Sudan during the period November 2012 - May 2014. Participants 
gave consent then were interviewed for socio- demographic information and examined for 
skin, cardio-pulmonary, renal, neurological, and hematological manifestations to fulfill the 
ACR criteria for classification SLE. A Blood sample for full blood count, renal function, 
inflammatory markers, and antinuclear antibody profile including anti-Ro (SSA) was taken. 
This study was approved by the ethical committees of Omdurman and Military Teaching 
Hospitals. The Statistical Package for Social Sciences (SPSS) version 19 was used for data 
analysis. The Chi- square test was used for the relationship between categorical variables, and 
then Pearson's correlation was applied for different variables. 
Results: Mean age was 36.4±11.6years, ranged from 18- 65 years. Female dominance is 
obvious (94.2%). Sixty six (76.7%) of subjects had arthritis, 45(52.3%) had oral or nasal 
ulcers, 35(40.7%) had malar rash, 31(36%) had photosensitive rash, while discoid rash was 
reported in 17(19.8%). 
Twenty nine (33.7%) of SLE patients were positive for anti-Ro antibodies. The positive 
percentage was 100%, 50%, 45.8% and21.1% in patients with pericarditis, renal involvement, 
pleurisy and neuro-psychiatric manifestations respectively. While anti- Ro antibodies were 
detected in 35.9% of patients with positive anti- nuclear antibodies. 
Conclusion: In the present study no association was found between anti-Ro antibody and the 
various manifestations of SLE. Larger multicenter studies are needed to assess the occurrence 
of anti-Ro antibodies in SLE, and their relationship with disease activity. 
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ystemic lupus erythematosus (SLE) 
is a chronic remitting and relapsing 
auto-immune disease that can affect 
__________________________________________________________  
1. Department of Internal Medicine, Faculty of 
Medicine, O.I.U, Omdurman, Sudan 
2. Department of Internal Medicine, Faculty of 
Medicine, University of Tabuk, Tabuk, KSA 
3. Department of Immunology, Omdurman 
Teaching Hospital, Omdurman, Sudan. 
 4. Department of Internal Medicine, College of 
Medicine, Aljouf University, Sakaka, Al-Jouf,KSA  
*Correspondence to: Abdelsalam Nail   
E-mail: abdelsalamnail@yahoo.com 
almost any organ in the body1. It usually 
affects young females, the cause is 
unknown but interaction of, genetic, 
environmental, and hormonal factors are 
blamed2. 
The outcome of this multi-organ disease 
varies according to race and gender. 
African Americans and those of lower 
education and socio-economic class had 
poorer clinical status including lupus 
nephropathy3. Although the incidence 
varies considerably, it is relatively more 
S
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common in Asians, and it is increasingly 
(the incidence is nearly tripled in the last 
40 years of the previous century) detected 
due to improvement in diagnostic 
measures4. The American College of 
Rheumatology (ACR) criteriawere used 
for lupus diagnosis. 
Ro- antigen is among many antigens that 
can be detected in SLE patients, with anti-
Ro antibodies amounting to 90%in some 
patients 6. Although anti-Ro antibodies can 
be detected earlier than other antibodies, 
and even before the diagnosis of SLE7, 
still their role is to be determined. 
Some previous studies suggest close 
correlation between anti-Ro antibodies and 
late onset SLE, with the onset of 
symptoms after the age of 50, but there is 
conflicting evidence between the 
correlation of anti-Ro antibodies and 
disease activity during the course of 
systemic lupus erythematosus8. 
In SLE anti-Ro antibodies have been 
reported to be associated with: 
photosensitivity, sub-acute cutaneous 
lupus erythematosus, cutaneous vasculitis 
(palpable purpura), hematological 
disorders, and interstitial pneumonitis, 
although no evidence of direct 
involvement of the antibodies in the 
pathogenesis of pulmonary disease, no 
erosive deforming arthritis, and passively 
transferred autoimmune disease that occurs 
in some babies born to mothers with anti-
Ro antibodies9, 10, 11, 12. 
In the 1970s, due to the use of mouse 
tissue as a substrate for antinuclear 
antibodies (ANA) testing there were 
several reports of patients who met the 
American College of Rheumatology 
criteria for classification of SLE, but were 
persistently negative for ANA. By 
comparison, anti-Ro /SSA antibodies were 
found in most of these patients when a 
human cell line extract was used as the 
substrate for the Ro antigen13.                 
As per our knowledge there are no studies 
that estimated the occurrence of anti-Ro 
antibodies in patients with SLE, and its 
relation to different components of the 
American Association of Rheumatology in 
Sudan. In the present research we studied 
the relationship of anti-Ro antibodies to 
different criteria of (ACR). 
MATERIALS AND METHODS: 
A total of 86 patients known to have 
systemic lupus erythematosus on 
medications (including disease modifying 
drugs), and regular follow-up, recruited 
from the rheumatic departments of 
Omdurman Teaching Hospital, and the 
Military Hospital during the period from 
November 2012 to May 2014. Children as 
well as patients with other connective 
tissue disorders were not included. 
Participants gave consent then interviewed 
and examined by the researcher. 
Information collected includes: socio- 
demographic, skin manifestations of lupus, 
cardio-pulmonary, renal, neurological, and 
hematological manifestations to fulfill the 
American College of Rheumatology 
Classification (ACR) criteria for systemic 
lupus erythematosus5. A Blood sample for 
full blood count, renal function, 
inflammatory markers, and antinuclear 
antibody profile was taken. Anti-Ro (SSA) 
was measured by Euroimmun Anti-Ro 
antibodies ELISA.  This study was 
approved by the ethical committees of 
Omdurman Teaching and Military 
Hospitals. The Statistical Package for 
Social Sciences (SPSS) version 19 was 
used for data analysis. Descriptive analysis 
was done for all variables, then Chi-square 
test was applied for categorical data, and 
correlation was tested byPearson's 
correlation.   
RESULTS: 
Mean age of 86 patients was 36.4±11.6, 
ranged from 18- 65 years. Female 
dominance  is obvious  (94.2%). Sixty   six
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Table (1): The clinical and laboratory findings among the study group according to ACA 
criteria 
No (%) Criterion 
45(52.3%) Oral and/or nasal ulcers 
66 (76.6%) Arthritis 
31 (36%) Photosensitive rash 
17 (19.8%) Discoid rash 
35 (40.7%) Malar rash 
19 (22.1%) Neuro-psychiatric disorders 
14 (16.3%) Renal involvement 
 2(2.3%) Pericarditis 
24 (27.9%) Pleurisy 
64 (74%) Antinuclear antibodies 
 Hematological manifestations 
28 (32.6%)   Anemia 
11 (12.8%)   Leucopenia 
5 (5.8%)   Thrombocytopenia 
 Immunological phenomena 
31 (36%)   dsDNA 
9 (10.5%)   Anti-phospholipids antibodies 
12 (14%)   Anti-Smith (SM) Antibodies 
29 (33.7%)   Anti-Ro antibodies 
Table (2): The prevalence of anti-Ro antibodies among patients in relation to ACA criteria 
Anti-Ro positive No (%) Criterion 
18 (40%) 45(52.3%) Oral and/or nasal ulcers 
21(31.8%) 66 (76.6%) Arthritis 
11 (35.5%) 31 (36%) Photosensitive rash 
8 (47.1%) 17 (19.8%) Discoid rash 
15 (42.9%) 35 (40.7%) Malar rash 
4 (21.1%) 19 (22.1%) Neuro-psychiatric disorders 
7 (50%) 14 (16.3%) Renal involvement 
2 (100%) 2 (2.3%) Pericarditis 
11 (45.8%) 24 (27.9%) pleurisy 
23 (35.9%) 64 (74%) Antinuclear antibodies 
  Hematological manifestations 
10 (35.7%) 28 (32.6%)   Anemia 
6 (54.5%) 11 (12.8%)   Leucopenia 
1 (20%) 5 (5.8%)   Thrombocytopenia 
  Immunological phenomena 
10 (32.3%) 31 (36%)   dsDNA 
5 (55.6%) 9 (10.5%)   Anti-phospholipids antibodies 
3 (25%) 12 (14%)   Anti-Smith (SM) Antibodies 
 (76.7%) of subjects had arthritis, 
45(52.3%) had oral or nasal ulcers, 
35(40.7%) had malar rash, 31(36%) had 
photosensitive rash, while discoid rash was 
reported in 17(19.8%), Table (1) 
highlighted the (ARC) criteria of subjects. 
Twenty nine (33.7%) of SLE patients were 
positive for anti-Ro antibodies (all 
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females), almost 100% of patients with 
pericarditis had positive anti-Ro 
antibodies, 50% of those with renal 
involvement had positive antibodies, while 
45.8% of patients with pleurisy had 
positive anti-Ro antibodies. Similarly 
21.1% of patients with neuro-psychiatric 
manifestations showed positive antibodies, 
whereas anti- Ro antibodies was detected 
in 35.9% of patients with positiveanti- 
nuclear antibodies. Table (2) demonstrates 
the prevalence of anti-Ro antibodies 
among patients according to ARA criteria. 
DISCUSSION: 
It is suggested that anti-Ro antibodies are 
associated with late onset systemic lupus 
erythematosus with symptoms after the 
age of 50 years, there are conflicting data 
as to the correlation of these antibodies 
with disease activity during the course of 
SLE6. 
The mean age at diagnosis was 36.4±11.6 
years similar to Kaballo et al7, and 
Houman et al8. 
In the present study, female dominance is 
obvious (94.2%) with female/male ratio 
16.2:1. Twenty nine (35.8%) of female 
were positive for anti-Ro antibodies, in 
accordance with previous studies9, 10. 
In the current study 33.7% of SLE patients 
were positive for anti-Ro antibodies, this 
result is lower than what is reported by 
Alarfag et al11 in Saudi Arabia and Alsaleh 
et al9 in United Arab Emirates who found 
that, anti-Ro antibodies were positive in 
53.1% and  52.3% respectively, but is 
higher than what is reported by Kurien12 
where anti-Ro antibodies were present in 
18.8% of lupus patients.The variation can 
be explained by the age, ethnicity, drugs, 
the method used to detect Anti-Ro, and 
fluctuation of anti-Ro antibodies through 
the course of the disease. In humans, a 
decrease in autoantibody titers has been 
shown during the course of MMF 
therapy12. 
In this study  leucopenia was present in 
54.5% of patients with anti-Ro positive 
SLE, in agreement with Kurien et al, who 
stated that neutropenia is present  in 6/13 
(46.1%) of anti-Ro positive SLE patients13. 
Our study demonstrated skin 
manifestations ranged from 35.5% - 47.1% 
of anti-Ro positive patients, and arthralgia 
was present in 31.8%. These results are in 
agreement with a study published by 
Popovic et al14, which showed skin 
symptoms in 42%, and arthralgia in 31% 
of anti-Ro positive patients. 
In the present study no correlation was 
found between anti-Ro antibody and the 
various manifestations of systemic lupus 
erythematosus, in agreement with Baptiste 
et al15. Additionally Hedpeth et al 
concluded that, no correlation between 
interstitial pneumonitis and anti-Ro 
antibodies in accordance with the present 
findings16. 
Our study is in contradiction with previous 
studies which showed correlation of anti-
Ro antibodies with photosensitive rash 17, 
cutaneous vasculitis18, and hematological 
disorders (anemia, neutropenia, and 
thrombocytopenia)13.  
Limitations of the study are the small size 
of the sample and it was conducted at two 
rheumatic centers, so generalization cannot 
be insured. Larger multicenter studies are 
needed to assess the occurrence of anti-Ro 
antibodies in systemic lupus 
erythematosus, and their relationship with 
disease activity in Sudan. 
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